Education IT Medical Provider Relationship 
GeriPal
DECEMBER 15, 2022
Summary Transcript Summary. We’ve talked at length on prior podcasts about the failures of aducnumab, Biogen, and the FDA’s decision to approve it. . But wait, there’s a shiny new anti-amyloid drug, lecanemab! (No No it’s not just the French version of Aducanumab). . In an article in the NEJM (a published article this time, wonder of wonders!)
GeriPal
DECEMBER 8, 2022
Unpacking characteristics of spirituality through the lens of persons of colour living with serious illness: The need for nurse-based education to increase understanding of the spiritual dimension in healthcare. Summary Transcript Summary. Eric and I weren’t sure what to call this podcast – storytelling and medicine? Wonderful work.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
GeriPal
FEBRUARY 20, 2025
Mariah discussed her JAGS paper on applying a trauma-informed approach to home visits. Kate and Ashwin talked about their research on the prevalence of lifetime trauma and its association with physical and psychosocial health among adults at the end of life. Mariah, welcome to the GeriPal Podcast. Mariah 00:29 Glad to be here. Here we go.
GeriPal
JUNE 6, 2024
Don Dizon, oncologist specializing in pelvic malignancies at Brown, suggests speaking in plain language, starting by normalizing sexual health issues, to paraphrase, “Many of my patients experience issues with intimacy and sexual health. Is that an issue for you? I’m happy to talk about it at any time.” This is Eric Widera. Ra ra ra ra.
FDA Law Blog
MAY 26, 2025
Even if otherwise truthful, the promotion of off-label uses of hormones-including through informal campaigns like those conducted by sales reps or under the guise of sponsored continuing medical education courses-run afoul of the FDAs prohibitions on misbranding and mislabeling. First, it direct[s] all U.S. MedImmune, Inc.
Expert insights. Personalized for you.
105 
Let's personalize your content